Viscum album [L.] extract therapy in patients with locally advanced or metastatic pancreatic cancer: A randomised clinical trial on overall survival

European Journal of Cancer

Volumn 49, Issue 18, 2013, Pages 3788-3797

  Troger W ^a   Galun, D ^b   Reif, M ^c   Schumann, A ^c   Stankovic N ^d   Milicevic M ^b,e  

^a Clinical Research Dr Tröger   (Germany)

^b CLINICAL CENTER OF SERBIA   (Serbia)

^c Institute for Clinical Research   (Germany)

^d CLINICOBSS ^*  (Serbia)

^e UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Mistletoe; Pancreatic neoplasm; Randomised controlled trial; Survival analysis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; VISCUM ALBUM EXTRACT;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANXIETY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BRAIN INFARCTION; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; FATIGUE; FEMALE; HEADACHE; HUMAN; JAUNDICE; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; NAUSEA AND VOMITING; OVERALL SURVIVAL; PAIN; PANCREAS CANCER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SURVIVAL RATE; UPPER ABDOMINAL PAIN; URINARY TRACT INFECTION; VERTIGO; WEIGHT REDUCTION;

MISTLETOE; PANCREATIC NEOPLASM; RANDOMISED CONTROLLED TRIAL; SURVIVAL ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; BACK PAIN; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEADACHE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; PLANT EXTRACTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VISCUM ALBUM;

EID: 84888015440     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.06.043     Document Type: Article

References (50)

1. S. Bayraktar, U.D. Bayraktar, and C.M. Rocha-Lima Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer World J Gastroenterol 16 6 2010 673 682
2. S. Cascinu, M. Falconi, V. Valentini, and S. Jelic Pancreatic cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 21 Suppl. 5 2010 v55 v58
3. T. Conroy, F. Desseigne, and M. Ychou FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer N Engl J Med 364 19 2011 1817 1825
4. J. Richter, and M.W. Saif Locally advanced pancreatic adenocarcinoma: where are we and where are we going? Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010 JOP 11 2 2010 Mar 5 139 143
5. A.D. Jacobs, H.A. Burris III, and S. Rivkin A randomized phase III study of rubitecan (ORA) vs. best choice (BC) in 409 patients with refractory pancreatic cancer report from a North-American multi-center study J Clin Oncol 22 2004 4013
6. U. Pelzer, I. Schwaner, and J. Stieler Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group Eur J Cancer 47 2011 1676 1681
7. S. Boeck, C.J. Bruns, and M. Sargent Current oncological treatment of patients with pancreatic cancer in germany: results from a national survey on behalf of the Arbeitsgemeinschaft Internistische Onkologie and the Chirurgische Arbeitsgemeinschaft Onkologie of the Germany Cancer Society Oncology 77 1 2009 40 48
8. G.M. Cragg, and D.J. Newman Plants as a source of anti-cancer agents J Ethnopharmacol 100 1-2 2005 72 79
9. G.S. Kienle, and H. Kiene Review article: influence of Viscum album L (European mistletoe) extracts on quality of life in cancer patients: a systematic review of controlled clinical studies Integr Cancer Ther 9 2 2010 142 157
10. A. Büssing Mistletoe. The genus Viscum 2000 Hardwood Academic Publishers Amsterdam p. 1-265
11. A. Büssing, M. Wagner, and B. Wagner Induction of mitochondrial Apo2.7 molecules and generation of reactive oxygen-intermediates in cultured lymphocytes by the toxic proteins from Viscum album L Cancer Lett 139 1 1999 79 88
12. G.S. Kienle, and H. Kiene Die Mistel in der onkologie - fakten und konzeptionelle grundlagen 2003 Schattauer Verlag Stuttgart p. 1-749
13. A. Thies, P. Dautel, A. Meyer, U. Pfuller, and U. Schumacher Low-dose mistletoe lectin-I reduces melanoma growth and spread in a scid mouse xenograft model Br J Cancer 98 1 2008 106 112
14. M. Rostock, R. Huber, and T. Greiner Anticancer activity of a lectin-rich mistletoe extract injected intratumorally into human pancreatic cancer xenografts Anticancer Res 25 3B 2005 1969 1975
15. H. Matthes, D. Buchwald, F. Schad, and E. Jeschke Intratumorale applikation von Viscum album L. (Mistelgesamtextrakt; Helixor M) in der therapie des inoperablen pankreaskarzinom Z Gastroenterol 45 2007 http://dx.doi.org/10. 1055/s-2007-988162
16. P.J. Mansky, M.R. Blackman, J. Grem, S.M. Swain, and B.P. Monahan NCCM/NCI phase I study of mistletoe extract and gemcitabine in patients with advanced solid tumors J Clin Oncol 28 15 2010 2559
17. G.S. Kienle, R. Grugel, and H. Kiene Safety of higher dosages of Viscum album L. in animals and humans - systematic review of immune changes and safety parameters BMC Complement Altern Med 11 1 2011 72
18. M. Rostock, and R. Huber Randomized and double-blind studies - demands and reality as demonstrated by two examples of mistletoe research Forsch Komplementärmed Klass Naturheilkd 11 Suppl. 1 2004 18 22
19. Guidance for Industry. Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM071590.pdf 2007 May.
20. H. Matthes, W.E. Friedel, P.R. Bock, and K.S. Zanker Molecular mistletoe therapy: friend or foe in established anti-tumor protocols? A multicenter, controlled, retrospective pharmaco-epidemiological study in pancreas cancer Curr Mol Med 10 4 2010 430 439
21. G. Schaefermeyer, and H. Schaefermeyer Treatment of pancreatic cancer with Viscum album (Iscador): a retrospective study of 292 patients 1986-1996 Complement Ther Med 6 1998 172 177
22. L.S. Freedman Tables of the number of patients required in clinical trials using the logrank test Stat Med 1 2 1982 121 129
23. K.K. Lan, and D.L. DeMets Discrete sequential boundaries for clinical trials Biometrika 70 3 1983 659 663
24. S.S. Emerson, and T.R. Fleming Parameter estimation following group sequential hypothesis testing Biometrika 77 4 1990 875 892
25. A. Hrobjartsson, and P.C. Gotzsche Placebo interventions for all clinical conditions Cochrane Database Syst Rev 20 1 2010 CD003974
26. R. Grossarth-Maticek, and R. Ziegler Randomised and non-randomised prospective controlled cohort studies in matched-pair design for the long-term therapy of breast cancer patients with a mistletoe preparation (Iscador): a re-analysis Eur J Med Res 11 11 2006 485 495
27. G.S. Kienle, F. Berrino, and A. Büssing Mistletoe in cancer - a systematic review on controlled clinical trials Eur J Med Res 8 3 2003 109 119
28. G.S. Kienle, and H. Kiene Systematic reviews on mistletoe in cancer - what implications for future research can be drawn? Phytomedicine (Jena) 14 Suppl. 2 2007 11
29. U.R. Kleeberg, S. Suciu, and E.B. Bröcker Final results of the EORTC 18871/DKG 80-1 randomised phase III trial: rIFN-a2b versus rIFN-g versus Iscador M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis Eur J Cancer 40 2004 390 402
30. M.K. Steuer-Vogt, V. Bonkowsky, and P. Ambrosch The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: a randomised controlled clinical trial Eur J Cancer 37 1 2001 23 31
31. M.C. Fung, S. Takayama, and H. Ishiguro Chemotherapy for advanced or metastatic pancreatic cancer: analysis of 43 randomized trials in 3 decades (1974-2002) Gan To Kagaku Ryoho 30 8 2003 1101 1111
32. J.R. Andersen, A. Friis-Moller, and S. Hancke A controlled trial of combination chemotherapy with 5-FU and BCNU in pancreatic cancer Scand J Gastroenterol 16 8 1981 973 975
33. A. Andren-Sandberg, J.T. Holmberg, and I. Ihse Treatment of unresectable pancreatic carcinoma with 5-fluorouracil, vincristine, and CCNU Scand J Gastroenterol 18 5 1983 609 612
34. T.E. Ciuleanu, A.V. Pavlovsky, and G. Bodoky A randomised phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine Eur J Cancer 45 9 2009 1589 1596
35. A.D. Gilliam, P. Broome, and E.G. Topuzov An international multicenter randomized controlled trial of G17DT in patients with pancreatic cancer Pancreas 41 3 2012 374 379
36. B. Glimelius, K. Hoffman, and P.O. Sjoden Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer Ann Oncol 7 6 1996 593 600
37. M. Huguier, A. Barrier, and R. Valinas Randomized trial of 5-fluorouracil, leucovorin and cisplatin in advanced pancreatic cancer Hepatogastroenterology 48 39 2001 875 878
38. H. Koeppler, M. Duru, and M. Grundheber Palliative treatment of advanced pancreatic carcinoma in community-based oncology group practices J Support Oncol 2 2 2004 159 163
39. C.N. Mallinson, M.O. Rake, and J.B. Cocking Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial Br Med J 281 6255 1980 1589 1591
40. K. Matsumoto, Y. Miyake, and H. Kato Effect of low-dose gemcitabine on unresectable pancreatic cancer in elderly patients Digestion 84 3 2011 230 235
41. S.S. Negi, A. Agarwal, and A. Chaudhary Flutamide in unresectable pancreatic adenocarcinoma: a randomized, double-blind, placebo-controlled trial Invest New Drugs 24 3 2006 189 194
42. K.R. Palmer, M. Kerr, and G. Knowles Chemotherapy prolongs survival in inoperable pancreatic carcinoma Br J Surg 81 6 1994 882 885
43. L. Rosenberg, A.N. Barkun, M.H. Denis, and M. Pollak Low dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreas Cancer 75 1 1995 23 28
44. M. Shimoda, M. Katoh, J. Kita, T. Sawada, and K. Kubota The Glasgow Prognostic Score is a good predictor of treatment outcome in patients with unresectable pancreatic cancer Chemotherapy 56 6 2010 501 506
45. H. Shinchi, S. Takao, and H. Noma Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer Int J Radiat Oncol Biol Phys 53 1 2002 146 150
46. T. Takada, Y. Nimura, and H. Katoh Prospective randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C for non-resectable pancreatic and biliary carcinoma: multicenter randomized trial Hepatogastroenterology 45 24 1998 2020 2026
47. O.M. Taylor, E.A. Benson, and M.J. McMahon Clinical trial of tamoxifen in patients with irresectable pancreatic adenocarcinoma. The Yorkshire Gastrointestinal Tumour Group Br J Surg 80 3 1993 384 386
48. N. Tsavaris, K. Tentas, and M. Tzivras Combined epirubicin, 5-fluorouracil and folinic acid vs no treatment for patients with advanced pancreatic cancer: a prospective comparative study J Chemother 10 4 1998 331 337
49. P. Wang, Z.Q. Meng, and Z. Chen Survival rate of pancreatic cancer in elderly patients Hepatogastroenterology 55 82-83 2008 681 686
50. B.H. Weinerman, and R.E. MacCormick A phase II survival comparison of patients with adenocarcinoma of the pancreas treated with 5-fluorouracil and calcium leucovorin versus a matched tumor registry control population Am J Clin Oncol 17 6 1994 467 469